Hemostasis Products Market Analysis

Hemostasis Products Market Analysis

Topical hemostasis products market is estimated to reach over USD 2 billion by 2032 due to advantages, such as ease of application, quick action, and reduced risk of complications. Moreover, the rising number of accidents worldwide coupled with the increasing incidence of surgeries along with the surging need of minimizing blood loss, reducing transfusions, and accelerating patient recovery. According to the National Highway Traffic Safety Administration, 31,785 persons died in traffic accidents in the first nine months of 2022.
 

Hemostasis products market size from the surgery segment is expected to exceed USD 988 million by 2032 due to the increasing number of more advanced and intricate surgeries to treat multiple diseases. The rising prevalence of cardiovascular and orthopedic surgeries as well as general procedures has resulted in the sustained demand for hemostasis products. According to the Lancet Commission, the global burden of surgically treatable diseases is estimated to rise by 60% in 2030. 
 

North America hemostasis products market size is expected to record 5.9% CAGR from 2023-2032. The presence of large geriatric population base coupled with lifestyle-related factors, such as obesity and sedentary habits are contributing to the increasing incidence of cardiovascular diseases. For instance, in July 2023, Baxter International Inc., a worldwide leader in surgical innovation, launched PERCLOT Absorbable Hemostatic Powder, a ready-to-use product developed for patients with intact coagulation to treat minor bleeding in the U.S.,